Application of labeled trastuzumab to diagnose breast cancer in HER2 positive cases

A clinical trial of a diagnostic radiopharmaceutical (64Cu-DOTA-Trastuzumab) in patients with metastatic breast cancer and HER2-positive

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180818040823N2

Enrollment

Registered

2020-12-23

Start date

2021-01-20

Completion date

Unknown

Last updated

2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic breast cancer. Malignant neoplasm of breast

Interventions

Intervention group: In this study, 5 mg of 64Cu-DOTA-trastuzumab radiopharmaceutical with a dose of 500-300 MB / h MBq, is injected into 22 patients with metastatic breast cancer and HER2 receptor. Th

Eligibility

Sex/Gender

Female

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patient with metastatic breast cancer and HER2 receptor stage 4 No previous treatment with Herceptin Negative estrogen and progesterone receptors

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Uptake of radiopharmaceutical in lesions. Timepoint: At imaging time (60 minutes after injection). Method of measurement: Observation and semi-quantification using SUV.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehrshad Abbasi

Tehran University of Medical Sciences

meabbasi@tums.ac.ir+98 21 6657 5102

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026